NCT02210858View on ClinicalTrials.gov

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

November 12, 2004

Study Completion Date

March 31, 2017

Conditions
Accelerated Phase of DiseaseAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelomonocytic LeukemiaChronic Phase of DiseaseMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableRecurrent Disease
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Tipifarnib

Given PO

Trial Locations (2)

14642

University of Rochester, Rochester

94304

Stanford Cancer Institute, Palo Alto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02210858 - Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | Biotech Hunter | Biotech Hunter